Back to News
Market Impact: 0.15
Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market
Source: fool.com
Healthcare & Biotech
Regeneron has a leading weight-loss candidate that could offer patients fewer side effects, though the article provides no supporting data or trial results. The company also has another investigational weight-loss medicine designed to help preserve lean muscle mass.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
REGN0.45
More News
- Capital One, General Motors are among the stocks reporting this week with momentum. Here are the others
- Crushed tech stocks bounce — plus, new doctor survey keeps us positive on Lilly
- Merck KGaA to acquire Silence Therapeutics for $1.3 billion
- Disc Medicine surges 38% after bitopertin clears Phase 3 trial endpoints
- Silence Therapeutics jumps 59% on Merck takeover
- Goldman says play defense with these stocks if you're worried about the AI bull failing